Company Long-Term Loans and Borrowings: Reata (RETA)

Reata Pharmaceuticals (RETA) focuses on therapies for rare brain and nerve pathologies. This chart illustrating the price evolution of the stock is based on the commercial success of Skyclarys and therapy accessibility for patients, where the indicator stands at 0.23. The company is developing innovations to protect neurons from oxidative stress. Active growth is driven by filling vacant market niches by 2026 through its current drug portfolio.

This indicator measures the total volume of liabilities with a maturity of more than one year. It determines the long-term solvency and the level of financial leverage of the organization. By analyzing the statistics of the business's long-term borrowed capital, an investor assesses the risks of cash flow gaps. The stability of this metric confirms the resilience of Reata Pharmaceuticals (RETA). A diversified development portfolio and the presence of commercial products allow the company to effectively manage its debt load.